Climb Bio, Inc.

Informe acción NasdaqGM:CLYM

Capitalización de mercado: US$502.5m

Climb Bio Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Aoife Brennan

Chief Executive Officer (CEO)

US$2.9m

Compensación total

Porcentaje del salario del CEO22.91%
Permanencia del CEO1.9yrs
Participación del CEO0.1%
Permanencia media de la direcciónless than a year
Promedio de permanencia en la Junta Directiva1.7yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Apr 16

Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway

Summary Climb Bio, Inc. maintains a Buy rating, driven by budoprutug’s strong phase 1b and long-term data in primary membranous nephropathy [pMN]. CLYM’s phase 2 PrisMN trial in pMN, with initial data expected 2H 2026, is a key catalyst; expansion into SLE and ITP offers additional upside. Budoprutug’s versatility, including a subcutaneous formulation and broad B-cell depletion, positions CLYM for competitive advantage in autoimmune disorders. With $160.7M in cash, CLYM is funded into 2028, reducing near-term dilution risk and supporting execution on multiple clinical milestones. Read the full article on Seeking Alpha
Artículo de análisis • Feb 07

Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 23

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Summary Eliem Therapeutics, founded in 2019, shifted focus to autoimmune diseases with the acquisition of Tenet Medicines and its lead molecule, budoprutug. Budoprutug targets CD19-positive B cells, aiming to treat SLE, ITP, and MN by reducing pathogenic autoantibodies and improving disease symptoms. Early clinical trials for MN showed promising results, with 60% of patients achieving complete remission of proteinuria, supporting further development. Despite a decent market cap and cash reserves, ELYM's early-stage status and single-molecule focus make it a cautious watch rather than an immediate investment. Read the full article on Seeking Alpha
Seeking Alpha • Jun 28

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Summary Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous nephropathy treatment market could reach $328.4 million by 2034. Two other large market indications that can be targeted using TNT119 are systemic lupus erythematosus and immune thrombocytopenia. Acquisition of Tenet Medicines and $120 million private placement agreement provide funding for operations into 2027, with cash on hand at $220 million. Read the full article on Seeking Alpha
Artículo de análisis • Feb 01

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Jun 24

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Artículo de análisis • Mar 08

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Artículo de análisis • Nov 18

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 15

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Eliem Therapeutics press release (NASDAQ:ELYM): Q2 GAAP EPS of -$0.56 misses by $0.09. Cash, cash equivalents and short- and long-term marketable securities was $134.7M as of June 30, 2022, as compared to $161.4M as of December 31, 2021. With the discontinuation of ETX-810, the company’s current cash, cash equivalents and short- and long-term marketable securities are now expected to fund operations into 2025.
Seeking Alpha • Aug 02

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Clinical-stage biotech Eliem Therapeutics (NASDAQ:ELYM) announced on Tuesday that the company decided to discontinue further development of its lead asset ETX-810 after the failure of a mid-stage trial for the candidate in lumbosacral radicular pain (LSRP). The primary endpoint of the 148-patient Phase 2a trial was the change in the weekly average of the daily pain score from baseline to week 4, measured using the Pain Intensity Numerical Rating Scale (PI-NRS). The results indicated that ETX-810 did not indicate a statistically significant separation from the placebo in the primary endpoint, according to the company. The results were similar to previously disclosed data from another Phase 2 trial in diabetic peripheral neuropathic pain (DPNP) which also indicated a lack of separation for the treatment arm compared to the placebo, the company said.
Seeking Alpha • Jul 11

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

SVB Leerink on Monday cut its price target on Eliem Therapeutics (NASDAQ:ELYM) to $9 from $13. The new PT - based on an SOTP analysis that forecasts cash flows into early 2040s, with 11% discount rate - implies potential upside of 142.6% to ELYM's last close. The brokerage reiterated its Outperform rating, in-line with sell-side rating of Strong Buy. "Given the decreased bioavailability of ETX-155 observed in the phase 1b interim data readout in photosensitive epilepsy, we lowered our POS for all ETX-155 programs, which resulted in our PT moving to $9," analyst Marc Goodman wrote in a note to clients. "We still expect data from ETX-810 in lumbosacral radicular pain in Q3, although expectations are low after the failed phase 2 study in diabetic peripheral neuropathy," he added. ELYM stock, which fell as much as 5.4% on Monday, has declined 67.3% YTD.

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Aoife Brennan en comparación con los beneficios de Climb Bio?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2026n/an/a

-US$53m

Dec 31 2025US$3mUS$670k

-US$60m

Sep 30 2025n/an/a

-US$51m

Jun 30 2025n/an/a

-US$47m

Mar 31 2025n/an/a

-US$93m

Dec 31 2024US$6mUS$330k

-US$74m

Compensación vs. Mercado: La compensación total ($USD2.92M) de Aoife está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.72M).

Compensación vs. Ingresos: La compensación de Aoife ha sido consistente con los resultados de la empresa en el último año.

CEO

Aoife Brennan (49 yo)

1.9yrs
Permanencia
US$2,922,223
Compensación

Dr. Aoife M. Brennan, M.D. M.B., Ch B., BAO, MMSc, MRCPI, is CEO, President at Climb Bio, Inc. (formerly known as Eliem Therapeutics, Inc.) and serves as its Director since June 2024 and served as its Inte...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Aoife Brennan
CEO, President & Directorno dataUS$2.92m0.10%
$ 506.3k
Susan Altschuller
CFO & Principal Accounting Officerless than a yearUS$1.53msin datos
Perrin Wilson
Chief Business Officer1.3yrsUS$1.59m0%
$ 0
Adam Villa
Senior VP of Technical Operationsless than a yearsin datossin datos
Chandra Adams
VP, General Counsel & Secretary1yrsin datossin datos
Ashley Jones
Senior VP of People & Workforce Strategyless than a yearsin datossin datos
Janaki Subramanyam
VP & Head of Regulatory Affairsno datasin datossin datos
Edgar Charles
Chief Medical Officerless than a yearsin datossin datos
Theresa Donegan
Vice President & Head of Qualityno datasin datossin datos
0.8yrs
Permanencia media
46yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de CLYM no se considera experimentado ( 0.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Aoife Brennan
CEO, President & Director1.9yrsUS$2.92m0.10%
$ 506.3k
Douglas Williams
Independent Chairman of the Board1.5yrsUS$205.33k0%
$ 0
Kimberlee Drapkin
Independent Director1.2yrsUS$170.57k0%
$ 0
Andrew Levin
Directorno dataUS$79.12k0%
$ 0
Alexander Cumbo
Independent Director1.2yrsUS$168.67k0%
$ 0
Stephen Thomas
Director1.9yrsUS$79.12k0.32%
$ 1.6m
Judith Dunn
Independent Director5.3yrsUS$89.75k0%
$ 0
1.7yrs
Permanencia media
54yo
Promedio de edad

Junta con experiencia: La junta directiva de CLYM no se considera experimentada (1.7 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/21 05:14
Precio de las acciones al final del día2026/05/21 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Climb Bio, Inc. está cubierta por 16 analistas. 14 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Colleen KusyBaird
Mayank MamtaniB. Riley Securities, Inc.
Julian HarrisonBTIG